Ascentage Pharma: Revenue up 29% YoY to $44.5M, with global trial progress and strengthened leadershipQuartr·20 hours agoAAPG-3.94%06855-2.38%
CSPC PHARMA 1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18AASTOCKS News·21 hours ago01093-2.68%
Daiwa Raises SBP GROUP TP to HKD7.2 as Interim Adjusted NP Far Beats ForecastsAASTOCKS News·22 hours ago01177+3.06%
CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billionPUBT·22 hours ago01093-2.68%
CSPC PHARMA Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in ChinaAASTOCKS News·1 day ago, 09:01 PM01093-2.68%
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rallyMarketWatch·1 day ago, 07:28 PMLLY-2.81%AMGN-1.95%
Sino Biopharma rebrands as SBP Group, targets global expansion via direct commercial rollout and partnershipsPUBT·19 hours ago01177+3.06%
11:55 ETSino Biopharmaceutical Limited stellt neue globale Marke SBP Group vor, um die internationale Expansion zu beschleunigenprnewswire·1 day ago, 10:56 AM01177+3.06%AZN-0.28%
Citi Raises SBP GROUP TP to HKD10.8 as Interim Profit Far Beats ExpectationsAASTOCKS News·22 hours ago01177+3.06%
Sino Biopharma rebrands global operations under SBP Group identityPUBT·1 day ago, 06:28 AMAZN-0.28%01177+3.06%
Ascentage Pharma posts interim results presentation on 1H 2026 business updatePUBT·1 day ago, 08:16 PMAAPG-3.94%06855-2.38%
ASCENTAGE 1H26 Loss Widens to RMB817 million; No Interim DividendAASTOCKS News·1 day ago, 09:11 PM06855-2.38%
Ascentage Pharma Lifts Revenue, Deepens Losses as U.S. Push and BTK Degrader Trials AdvanceTip Ranks·1 day ago, 06:07 PMAAPG-3.94%06855-2.38%
